



PERSONAL INFORMATION

Mother's Name	:
Mother Date Of Birth	://
Address :	
	E-Mail :
ID Number :	Social Security Number 💈
Father's Name	:
Baby's Name	:
Estimated Due Date	://
Date of Birth	://
Gestational Age at Deliv	erv :



PHYSICIAN INFORMATION

OB Name :	 Number :	Email :
MFM Name :	 Number :	Email :
Neonatologist Name :	 Number :	Email :
Pediatrician Name :	 Number :	Email :
Pediatric Hematologist Name	 Number :	Email :





MATERNAL ANTIBODY

Antibody ID	Last Known Titer	Highest Titer	Fe	etal Antigen S	tatus
			Positive	Negative	Unknown
			Positive	Negative	Unknown
			Positive	Negative	Unknown
			Positive	Negative	Unknown
			Positive	Negative	Unknown

Is bab	y at risk for HDF	N?
--------	-------------------	----

Unknown (monitor as if positive)



FETAL AND NEONATAL IMPLICATIONS

Yes

:

- Only antigen positive fetuses/neonates can be affected by the matching maternal antibody.
- Antigen negative fetuses/neonates are not at risk for HDFN, regardless of titer.

No

- For those with positive or unknown antigen status, HDFN can be more severe with critical titers (16 or above for all antibodies, 4 or above for Kell) or multiple maternal antibodies, and should be closely monitored accordingly.
- Babies born to mothers with titers below critical are still at risk and should receive close monitoring.
- Regardless of fetal antigen status, donor blood for the fetus or neonate must be cross matched for all maternal antibodies.

FETAL MONITORING FOR PATIENTS WITH CRITICAL TITER OR PREVIOUSLY AFFECTED PREGNANCY

Gestation	Date	PSV	М.о.М.



PRENATAL INTERVENTIONS

CVS	:	Yes	No
lf yes, date(s) of procedure	:		
Amniocentesis	:	Yes	No
If yes, date(s) of procedure	:		
Corticosteroids	:	Yes	No
If yes, date(s) of administration	:		
Maternal phenobarbital for fetal hepatic maturation?	:	Yes	No
lf yes, date(s) of procedure	:		
Intrauterine Blood Transfusion (IUT)	:	Yes	No
If yes, fill out chart below	:		



INTRAUTERINE BLOOD TRANSFUSIONS

	Date	Gestation	Starting Hct	Ending Hct	Medications Administered to Fetus
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					



NEONATAL & PEDIATRIC IMPLICATIONS

- Infants who have received intrauterine transfusions may have 100% donor blood at birth since most/all fetal red blood cells have been destroyed by maternal antibodies and have been replaced with antigen negative donor blood. DAT at birth may therefore be negative despite severe HDFN.
- Intrauterine transfusions can also affect neonatal blood typing and newborn screen, possibly causing inaccurate results, ie. O- blood type that changes once donor blood dies off, or false positive newborn screen for Carnitine Deficiency Disorder, etc.
- These tests can be readministered several weeks after the infant's last blood transfusion to ensure accurate results.





MFM NOTES TO NEONATAL/PEDIATRIC TEAM

gree to be contacted by neon	atal/pediatric providers? Yes)
FM Signature :	Date :	
atient Signature :	Date :	





BIRTH/NEONATAL

Date of Birth :	Gestational Age at Birth	:	
Birth Weight :	Time of Birth	:	
Delayed Cord Clamping? Yes	No		
	ONS		

Delayed cord clamping (30-60 seconds) may reduce the need for neonatal exchange or top-up transfusion in the HDFN neonate with history of intrauterine transfusion.

Cord Bloo	d Tested at Birth?	Yes	No			
lf no, whei	n were first labs drawn?					
DAT (DCT)	:			Bilirubin	:	
нст	:			HGB	:	

BILIRUBIN/ HYPERBILIRUBINEMIA



NEONATAL & PEDIATRIC IMPLICATIONS

- Baseline bilirubin should be checked at birth since hemolytic jaundice can present at birth or very soon afterwards
- Hemolytic jaundice presents differently than typical newborn jaundice and requires close monitoring and specialized treatment
- Bilirubin levels can rise rapidly in newborns with HDFN.

Age	Date	Time	Bilirubin	Phototherapy	IVIG	Exchange Transfusion





Age	Date	Time	Bilirubin	Phototherapy	IVIG	Exchange Transfusion

RBC/ HEMOLYTIC ANEMIA

NEONATAL, PEDIATRIC & HEMATOLOGY IMPLICATIONS

- Hemolytic anemia presents differently than iron deficiency anemia and requires specialized monitoring and treatment
- Newborns with HDFN (even those who didn't need IUTs) are at risk for high ferritin and iron overload, even when they are anemic. Iron supplementation is not a treatment for hemolytic anemia but could be utilized if blood tests confirm low ferritin levels in the infant.
- Neonates with HDFN are at risk for delayed onset hemolytic anemia and should have a follow up consult scheduled with a pediatric hematologist **before hospital discharge.**

Age	Date	Time	Hemoglobin	Hematocrit	Retic	Transfusion





Age	Date	Time	Hemoglobin	Hematocrit	Retic	Transfusion

HOSPITAL DISCHARGE

Date of Discharge	:	Discharging Physician :
Infant Age at Discharge	:	Last hgb/hct Before Discharge:
Last Bilirubin Before Discharge		Last Retic Before Discharge :

	PEDIATRIC & HEMATOLOGY IMPL	ICATIONS	
	 Neonates with HDFN are at risk for dela hematology or, in less severe cases, a pe discharge with proper transfer of fetal a One or more top-up transfusions may b hemoglobin/hematocrit levels are initial 	ediatrician knowledgeable in H nd neonatal health history. e necessary up to 3-4 months	IDFN monitoring prior to of age even if
Follow u	up consult with pediatric hematologist	scheduled?	Yes No
Appointmer	nt Date :	Hematologist Name	
Hematologi Number	ist :		



NEONATAL PROVIDER NOTES TO PEDIATRIC/HEMATOLOGY TEAM

Agree to be contacte	ed by hematology/ pe	diatric provide	rs? Yes	No
Neonatal Provider . Signature		Da	ce :	
Parent Signature :		——— Da	te :	
Neonatologist/ Hospital Pediatricia	transitioning care to	Pediatrician	collaborating with	Hematologist



POST DISCHARGE CARE

Date	Bilirubin	Hemoglobin	Hematocrit	Retic	Symptoms	Transfusion

Two subsequent rises in hgb/hct without transfusion?

No

Yes

HDFN RESOLVED

Hematologist/ Pediatrician Signature	:	Date :	
Parent Signature	:	Date :	
Hematol	ogist/ Pediatrician	releasing patient from care/ declaring HDFN resolved on —	Date